Results 271 to 280 of about 60,209 (283)
Some of the next articles are maybe not open access.
Sirolimus therapy in cardiac transplantation
Transplantation Proceedings, 2003Rapamycin powerfully inhibits the progression of antigen-activated T cells through the cell cycle. In animal heart transplantation models, rapamycin therapy has been associated with profound immunosuppressive effects on host humoral and cellular responses.
Bojan Vrtovec, B. Radovancevic
openaire +3 more sources
Distribution of sirolimus in rat tissue
Clinical Biochemistry, 1997To examine the distribution of sirolimus (SRL, rapamycin), an immunosuppressive macrolide antibiotic, in the tissues of adult male Wistar-Furth rats following continuous intravenous infusion (CIVI) and repeated daily peroral gavage (PO).Animals received 14-day courses of SRL by either CIVI (0.04-0.4 mg/kg/day) or PO (0.4-1.6 mg/kg/day) administration ...
Stanislaw M. Stepkowski +3 more
openaire +3 more sources
Sirolimus after kidney transplantation [PDF]
BMJ, 2014 An uncertain future for sirolimus and other mTOR inhibitors The risk of cancer is increased after kidney transplantation and is predominantly attributed to oncogenic immunosuppression.1 It is a leading cause of death for kidney allograft recipients, and analyses of transplant registry data suggest that mortality related to cancer is on the increase.2 ...
openaire +2 more sources
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
New England Journal of Medicine, 2011To the Editor: McCormack and colleagues (April 28 issue) 1 state that the decline in lung function in patients with lymphangioleiomyomatosis (LAM) resumed in the sirolimus group after treatment ended and paralleled the reduction in the placebo group. Figure 2A of the article shows the speed of forced expiratory volume in 1 second (FEV 1 ) in the two ...
openaire +4 more sources
Sirolimus in pediatric transplant recipients
Transplantation Proceedings, 2003The side effects of calcineurin inhibitors (CI) have a unique spectrum in pediatric recipients of organ transplants. These include a lifelong risk of mortality due to sepsis, a nearly 5% risk of renal failure from protracted exposure to CI, and a significantly higher risk of posttransplant lymphoproliferative disorder (PTLD) when compared with adults ...
openaire +3 more sources
Sirolimus in pediatric renal transplantation
Pediatric Transplantation, 2011Kasap B. Sirolimus in pediatric renal transplantation. Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S.Abstract: SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL
openaire +3 more sources
Population pharmacokinetics of sirolimus
Clinical Pharmacology & Therapeutics, 1998Elena V. Mishina +3 more
openaire +3 more sources
Sirolimus for Lymphangioleiomyomatosis Lesions
New England Journal of Medicine, 2008Jim J. Egan +2 more
openaire +2 more sources